Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 13,734 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 106
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more

Conditions: Acromegaly
Interventions: Octreotide capsules; Drug
Lead sponsor: Chiasma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more

Conditions: Substance Use Disorders
Interventions: IPS Plus Abstinence-Contingent Wage Supplement; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma, Astrocytoma, Grade IV
Interventions: EGFR(V)-EDV-Dox; Drug
Lead sponsor: Engeneic Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nicotine Dependence, Drug Abuse
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
Interventions: Itacitinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 60 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HCV
Interventions: Prophylaxis (P2W), Transmit and Treat (T&T); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 33
States / cities: Irvine, California • Sylmar, California • Denver, Colorado + 22 more

Conditions: Vestibular Schwannoma, Neurofibromatosis Type 2
Interventions: bevacizumab, laboratory biomarker analysis, quality-of-life assessment; Biological · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • Rockville, Maryland • Charlestown, Massachusetts

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 22
States / cities: Oakland, California • Orange, California • Aurora, Colorado + 19 more

Conditions: Osteoporosis Pseudoglioma Syndrome
Interventions: Human recombinant growth hormone; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Coronary Disease, Diabetes Mellitus
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 15,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more

Conditions: Cancer, Pain
Interventions: Modafinil; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Muscular Atrophy
Interventions: Onasemnogene Abeparvovec-xioi; Biological
Lead sponsor: Novartis Gene Therapies; Industry
Eligibility: 6 Months to 60 Months
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Orlando, Florida + 8 more

Conditions: Inpatients and Outpatients With Routine 12-lead ECG
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
Interventions: Tazemetostat; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Metabolic Syndrome
Interventions: Community-Based Exercise Program (C-FIT), Self-Help Exercise Program (HOME); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Polycystic Ovary Syndrome
Interventions: Elagolix, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • San Diego, California + 43 more

Conditions: Pemphigus Vulgaris (PV)
Interventions: Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 115
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 49
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 33 more

Conditions: Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions: BE1116, FFP; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more

Search by objective public record fields.

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

A Therapeutic Workplace to Address Poverty and Substance Use

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Growth Hormone for Osteoporosis Pseudoglioma Syndrome

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Modafinil in Opioid Induced Sedation

Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy

Personalized Risk Identification and Management for Arrhythmias and Heart Failure by ECG and MRI

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Evaluating the Effectiveness of a Community Exercise Program to Reduce the Risk of Metabolic Syndrome Among Black Americans

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)